Therapy for rheumatoid arthritis: Combinations of disease-modifying drugs and new paradigms of treatment

Seminars in Arthritis and Rheumatism

Volumn 21, Issue 2 SUPPL. 1, 1991, Pages 21-34

  Wilke, William S ^a   Clough, John D ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

"graduatedstep" strategy; combination therapy; Rheumatoid arthritis; strategies of treatment

Indexed keywords

ANTIRHEUMATIC AGENT; AURANOFIN; AZATHIOPRINE; CHLORAMBUCIL; CHLOROQUINE; CYCLOPHOSPHAMIDE; GOLD; HYDROXYCHLOROQUINE; METHOTREXATE; PENICILLAMINE; PREDNISOLONE; PREDNISONE; SALAZOSULFAPYRIDINE;

DRUG COMBINATION; DRUG COMPARISON; DRUG EFFICACY; DRUG TOXICITY; LEUKOPENIA; NAUSEA; PRIORITY JOURNAL; RASH; REVIEW; RHEUMATOID ARTHRITIS; STOMATITIS;

ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; AZATHIOPRINE; CLINICAL TRIALS; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; HUMAN; HYDROXYCHLOROQUINE; METHOTREXATE; PENICILLAMINE;

EID: 0026005868     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/0049-0172(91)90048-5     Document Type: Article

References (90)

1. Treatment of rheumatoid arthritis—1970
2. Outcome of attempts to treat rheumatoid arthritis with gold, penicillamine, sulfasalazine, or dapsone
3. Gold vs. d-penicillamine double blind study and follow-up
4. Methotrexate therapy in psoriatic arthritis: Double blind study on 21 patients
5. Resolve: Methotrexate is the drug of choice after NSAIDs in rheumatoid arthritis
6. Proposition: Methotrexate should not be the first second-line agent to be used in rheumatoid arthritis if NSAIDs fail
7. Criteria for initiating therapy with disease-modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis (RA)
8. Mortality and survival in rheumatoid arthritis. A 25-year prospective study of 100 patients
9. Is mortality increased in rheumatoid arthritis
10. Comparison of adverse reactions of methotrexate and other disease-modifying drugs
11. Longterm prospective trial of low-dose methotrexate in rheumatoid arthritis
12. Azathioprine in rheumatoid arthritis. A double-blind, cross-over study
13. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis
14. A controlled two-center trial of parenteral methotrexate therapy for refractory rheumatoid arthritis
15. Azathioprine in rheumatoid arthritis: Double-blind study of full vs. half doses vs. placebo
16. Combination of auranofin and methotrexate as initial DMARD in RA
17. 4
18. Chloroquine: Its effect on leukocyte auto and heterophagocytosis
19. Controlled trial of hydroxychloroquine and d-penicillamine singly and in combination in the treatment of rheumatoid arthritis
20. Combined d-penicillamine and chloroquine treatment of rheumatoid arthritis—A comparative study
21. Combination therapy with gold and hydroxychloroquine in rheumatoid arthritis: A prospective, randomized, placebo-controlled study
22. Chrysotherapy and concomitant use of antimalarial drug therapy in rheumatoid arthritis
23. Sulfasalazine alone or in combination with d-penicillamine in rheumatoid arthritis
24. Sulfasalazine in rheumatoid arthritis: Combination therapy with d-penicillamine or sodium aurothiomalate
25. Cyclophosphamide therapy for rheumatoid arthritis
26. Intensive immunosuppression in intractable rheumatoid arthritis
27. Combined disease-modifying chemotherapy for intractable rheumatoid arthritis
28. Clinical and immunological study of high dose azathioprine combined with gold therapy
29. Combination methotrexate and sulfasalazine in the management of rheumatoid arthritis: Case observations
30. Methotrexate toxicity in a patient receiving trimethoprim-sulfamethoxazole
31. Treatment of rheumatoid arthritis (RA) with combination of d-penicillamine (DPCN) and methotrexate (MTX)
32. The combined use of oral methotrexate and intramuscular gold in rheumatoid arthritis
33. The European experience
34. for the Cooperative Systematic Studies of the Rheumatic Diseases Comparison of auranofin methotrexate and the combination of both in the treatment of rheumatoid arthritis
35. Incidence of toxicity in patients with rheumatoid arthritis treated with methotrexate
36. Aspirin, hydroxychloroquine, and hepatic enzyme abnormalities with methotrexate in rheumatoid arthritis
37. Malignancy following treatment of rheumatoid arthritis with cyclophosphamide. Long-term case-control follow-up study
38. Low-dose prednisone therapy in rheumatoid arthritis: A double blind study
39. Corticosteroids in rheumatoid arthritis Is a trial of their “disease modifying” potential feasible?
40. Combined disease-modifying chemotherapy for intractable rheumatoid arthritis
41. Rheumatoid arthritis. Pathophysiology and implications for therapy
42. Intractable rheumatoid arthritis: Treatment with combined cyclophosphamide, azathioprine and hydroxychloroquine
43. Treatment of intractable rheumatoid arthritis with combined cyclophosphamide, azathioprine and hydroxychloroquine: A follow-up study
44. Single-agent versus combination cytotoxic therapy: The case for combination therapy
45. Low-dose cytotoxic drug combination therapy in intractable rheumatoid arthritis: Two years later
46. Low-dose cytotoxic drug combination therapy in rheumatoid arthritis
47. Combined cytotoxic therapy in rheumatoid arthritis (RA)
48. The combination of methotrexate (MTX) and azathiprine (AZA) for resistant rheumatoid arthritis (RA)
49. Combination chemotherapy for severe rheumatoid arthritis
50. Intractable RA—Treatment with combined methotrexate, azathioprine, and hydroxychloroquine
51. Intravenous administration of nitrogen mustard alone and in combination with corticotropin for rheumatoid arthritis
52. Chemotherapy in rheumatoid arthritis
53. Parenteral nitrogen mustard for inflammatory arthritis
54. Suppress rheumatoid inflammation early and leave the pyramid to the Egyptians
55. The effect of folic acid supplementation on toxicity of low-dose methotrexate in patients with rheumatoid arthritis
56. Folatesupplementation in methotrexate-treated rheumatoid arthritis patients
57. Methotrexate drug interactions
58. The effect of methotrexate on the bioavailability of oral 6-mercaptopurine
59. The development of disability in rheumatoid arthritis
60. Factors related to the progression of joint destruction in rheumatoid arthritis
61. Prognostic value of early features in rheumatoid disease
62. The natural history of rheumatoid arthritis. A 15 year follow-up study. The prognostic significance of features noted in the first year
63. Prognostic factors and diagnostic criteria in early rheumatoid arthritis
64. Longterm outcome of treating rheumatoid arthritis: Results after 20 years
65. Course and prognosis in rheumatoid arthritis. A further report
66. The assessment of rheumatoid arthritis: A study based on measurements of the serum acute phase reactants
67. Onset, early stages and prognosis of rheumatoid arthritis. A clinical study of 100 patients with 11-year follow-up
68. Prognosis in rheumatoid arthritis. A longitudinal study of newly diagnosed younger adult patients
69. Factors predicting a poor life prognosis in rheumatoid arthritis. An 8 year prospective study
70. Prediction of erosiveness and rate of development of new erosions in early rheumatoid arthritis
71. Preference for endpoint measures in clinical trials: Results of structured workshops
72. Articular indices of joint inflammation in rheumatoid arthritis. Correlation with the acute phase response
73. Rheumatoid arthritis: Relation of serum C-reactive protein and erythrocyte sedimentation rates to radiographic changes
74. Progression of radiological changes in rheumatoid arthritis
75. Does second-line therapy affect the radiological progression of rheumatoid arthritis?
76. Rheumatoid arthritis: Treatment which controls the c-reactive protein and erythrocyte sedimentation rate reduces radiological progression
77. Hand radiographs of 200 patients with rheumatoid arthritis repeated after an interval of one year
78. Radiographic changes in early rheumatoid disease
79. Effect of gold on progression of erosions in rheumatoid arthritis Better results with early treatment
80. Remodeling the pyramid—A concept whose time has come
81. Re-evaluating the therapeutic approach to rheumatoid arthritis: The “sawtooth” strategy
82. Gold vs. d-penicillamine double blind study and follow-up
83. Low-dose methotrexate treatment of rheumatoid arthritis. Long-term observations
84. Long-term outcome with gold thiosulfate and tiopronin in 200 rheumatoid patients
85. A three-year follow-up of patients allocated to placebo or oral or injectable gold therapy for rheumatoid arthritis
86. What should we hope to achieve when treating rheumatoid arthritis
87. Can we develop simple response criteria for slow acting anti-rheumatic drugs?
88. Therapeutic significance of laboratory results in rheumatic disease
89. Acta Radiol Diagn
90. Evidence of significant radiographic damage in rheumatoid arthritis within the first two years of disease